| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 6, 2025 | Klein Roger M. | 10% Owner | Sell | 9,000 | $10.65 | $95,885.00 | -5.5% | - | - | ||
| Nov 6, 2025 | TEVA Teva Pharmaceutical Industries Ltd | Mignone Roberto | Director | Sell | 200,000 | $24.11 | $4,821,880.00 | -28.8% | +42.9% | - | |
| Nov 6, 2025 | COLL Collegium Pharmaceutical, Inc | Tupper Colleen45 | EVP &Chief Financial Officer | Sell | 30,000 | $40.53 | $1,215,753.34 | -10.4% | +18.5% | - | |
| Nov 5, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 179,042 | $933.26 | $167,092,103.97 | - | +8.4% | - | |
| Nov 5, 2025 | NBIX Neurocrine Biosciences Inc | Rastetter William H48 | Director | Sell | 18,000 | $151.82 | $2,732,689.80 | -30.8% | -9.6% | - | |
| Nov 5, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 40,432 | $951.56 | $38,473,442.10 | - | +8.4% | - | |
| Nov 5, 2025 | LQDA Liquidia Corp | Saggar Rajeev | Chief Medical Officer | Sell | 71,381 | $27.00 | $1,927,287.00 | -14.5% | +76.5% | - | |
| Nov 5, 2025 | UTHR United Therapeutics Corp | Rothblatt Martine A | Chairperson &CEO | Sell | 8,000 | $436.05 | $3,488,422.80 | -36.0% | +6.9% | - | |
| Nov 5, 2025 | PAHC Phibro Animal Health Corp | Bendheim Jack49 | President And CEO | Sell | 7,040 | $42.16 | $296,778.35 | -2.7% | +0.4% | - | |
| Nov 4, 2025 | UTHR United Therapeutics Corp | Edgemond James | CFO And Treasurer | Sell | 21,000 | $436.09 | $9,157,821.35 | -11.4% | +8.6% | - | |
| Nov 4, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 526 | $910.72 | $479,038.19 | - | +15.1% | - | |
| Nov 4, 2025 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Executive Officer | Sell | 300 | $141.97 | $42,591.00 | -0.2% | -3.9% | - | |
| Nov 4, 2025 | PLNH Planet 13 Holdings Inc. | Wren Chris | VP Of Operations | Sell | 60,000 | $0.20 | $11,916.99 | -0.4% | - | - | |
| Nov 3, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 300,000 | $888.83 | $266,648,920.78 | - | +16.5% | - | |
| Nov 3, 2025 | MRK Merck & Co., Inc. | Williams David Michael | EVP,Chief Info&Digital Officer | Sell | 8,614 | $83.59 | $720,039.95 | -26.0% | +37.4% | - | |
| Nov 3, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $25.27 | $12,633.10 | -0.7% | +10.4% | - | |
| Nov 3, 2025 | UTHR United Therapeutics Corp | Benkowitz Michael | President And COO | Sell | 22,500 | $429.25 | $9,658,073.35 | -33.7% | +8.3% | - | |
| Nov 3, 2025 | ALKS Alkermes Plc. | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sell | 9,000 | $30.38 | $273,441.60 | -11.4% | +15.9% | - | |
| Nov 3, 2025 | UTHR United Therapeutics Corp | Rothblatt Martine A | Chairperson &CEO | Sell | 8,000 | $444.32 | $3,554,592.26 | -35.8% | +8.3% | - | |
| Oct 31, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 301,342 | $863.35 | $260,165,030.94 | - | +18.7% | - | |
| Oct 31, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Paolini John F.51 | Chief Medical Officer | Sell | 82,542 | $37.14 | $3,065,609.88 | -57.4% | +18.8% | - | |
| Oct 30, 2025 | UTHR United Therapeutics Corp | Mahon Paul A | EVP &General Counsel | Sell | 11,000 | $450.34 | $4,953,760.38 | -3.7% | +3.0% | - | |
| Oct 30, 2025 | UTHR United Therapeutics Corp | Rothblatt Martine A | Chairperson &CEO | Sell | 8,000 | $442.37 | $3,538,948.54 | -45.3% | +3.0% | - | |
| Oct 30, 2025 | PAHC Phibro Animal Health Corp | Bendheim Jack49 | President And CEO | Sell | 10,560 | $41.43 | $437,486.72 | -6.8% | -7.3% | - | |
| Oct 28, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | Chief Financial Officer | Sell | 100 | $41.00 | $4,100.00 | -0.3% | +9.6% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.